STOCK TITAN

LIVMARLI Now Approved in Japan for ALGS and PFIC

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags

Mirum Pharmaceuticals (NASDAQ: MIRM) announced that its partner Takeda Pharmaceutical has received approval from the Japanese Ministry of Health, Labour, and Welfare for LIVMARLI® (maralixibat) oral solution. The approval is for treating cholestatic pruritus in patients with Alagille syndrome (ALGS) and Progressive Familial Intrahepatic Cholestasis (PFIC) in Japan.

LIVMARLI becomes the first and only treatment available for these conditions in Japan. Under the exclusive license agreement signed in September 2021, Mirum will receive a percentage of Takeda's annual net sales. The medication is currently approved for ALGS-related pruritus in over 40 countries and for PFIC in more than 30 countries worldwide.

Mirum Pharmaceuticals (NASDAQ: MIRM) ha annunciato che il suo partner Takeda Pharmaceutical ha ricevuto l'approvazione dal Ministero della Salute, del Lavoro e del Welfare giapponese per la soluzione orale LIVMARLI® (maralixibat). L'approvazione riguarda il trattamento del prurito colestatico nei pazienti con sindrome di Alagille (ALGS) e colestasi intraepatica familiare progressiva (PFIC) in Giappone.

LIVMARLI diventa il primo e unico trattamento disponibile per queste condizioni in Giappone. In base all'accordo di licenza esclusiva firmato a settembre 2021, Mirum riceverà una percentuale delle vendite nette annuali di Takeda. Il farmaco è attualmente approvato per il prurito correlato ad ALGS in oltre 40 paesi e per PFIC in più di 30 paesi in tutto il mondo.

Mirum Pharmaceuticals (NASDAQ: MIRM) anunció que su socio Takeda Pharmaceutical ha recibido la aprobación del Ministerio de Salud, Trabajo y Bienestar de Japón para la solución oral LIVMARLI® (maralixibat). La aprobación es para tratar el prurito colestático en pacientes con síndrome de Alagille (ALGS) y colestasis intrahepática familiar progresiva (PFIC) en Japón.

LIVMARLI se convierte en el primer y único tratamiento disponible para estas condiciones en Japón. Según el acuerdo de licencia exclusiva firmado en septiembre de 2021, Mirum recibirá un porcentaje de las ventas netas anuales de Takeda. El medicamento está actualmente aprobado para el prurito relacionado con ALGS en más de 40 países y para PFIC en más de 30 países en todo el mundo.

Mirum Pharmaceuticals (NASDAQ: MIRM)는 파트너 Takeda Pharmaceutical이 일본 보건복지부로부터 LIVMARLI® (maralixibat) 경구 용액에 대한 승인을 받았다고 발표했습니다. 이 승인은 알라질 증후군(ALGS) 및 진행성 가족성 간내 담즙 정체(PFIC) 환자의 담즙 정체성 가려움증 치료를 위한 것입니다.

LIVMARLI는 일본에서 이러한 질환에 대한 첫 번째이자 유일한 치료제가 됩니다. 2021년 9월에 체결된 독점 라이센스 계약에 따라 Mirum은 Takeda의 연간 순매출의 일부를 받게 됩니다. 이 약물은 현재 40개국 이상에서 ALGS 관련 가려움증에 대해, 30개국 이상에서 PFIC에 대해 승인되었습니다.

Mirum Pharmaceuticals (NASDAQ: MIRM) a annoncé que son partenaire Takeda Pharmaceutical a reçu l'approbation du ministère japonais de la Santé, du Travail et du Bien-être pour la solution orale LIVMARLI® (maralixibat). Cette approbation concerne le traitement du prurit cholestatique chez les patients atteints du syndrome d'Alagille (ALGS) et de cholestase intra-hépatique familiale progressive (PFIC) au Japon.

LIVMARLI devient le premier et unique traitement disponible pour ces conditions au Japon. Selon l'accord de licence exclusive signé en septembre 2021, Mirum recevra un pourcentage des ventes nettes annuelles de Takeda. Le médicament est actuellement approuvé pour le prurit lié à l'ALGS dans plus de 40 pays et pour le PFIC dans plus de 30 pays à travers le monde.

Mirum Pharmaceuticals (NASDAQ: MIRM) gab bekannt, dass sein Partner Takeda Pharmaceutical die Genehmigung des japanischen Ministeriums für Gesundheit, Arbeit und Wohlfahrt für die orale Lösung LIVMARLI® (maralixibat) erhalten hat. Die Genehmigung gilt für die Behandlung von cholestatischem Juckreiz bei Patienten mit Alagille-Syndrom (ALGS) und progressiver familiärer intrahepatischer Cholestase (PFIC) in Japan.

LIVMARLI wird die erste und einzige Behandlung für diese Erkrankungen in Japan. Im Rahmen des im September 2021 unterzeichneten exklusiven Lizenzvertrags wird Mirum einen Prozentsatz von Takedas Jahresnettoverkauf erhalten. Das Medikament ist derzeit in über 40 Ländern für mit ALGS verbundenen Juckreiz und in mehr als 30 Ländern weltweit für PFIC zugelassen.

Positive
  • First-mover advantage as the only approved treatment for ALGS and PFIC in Japan
  • Partnership with major pharmaceutical company Takeda for commercialization
  • Revenue stream through percentage of annual net sales in Japan
  • Expanded global presence with approvals in 40+ countries for ALGS and 30+ for PFIC
Negative
  • Revenue dependent on Takeda's sales performance and execution

- LIVMARLI is the first and only treatment available for cholestatic pruritus in patients with Alagille syndrome and Progressive Familial Intrahepatic Cholestasis in Japan

FOSTER CITY, Calif.--(BUSINESS WIRE)-- Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced that its partner, Takeda Pharmaceutical Company Limited, has received approval by the Japanese Ministry of Health, Labour, and Welfare for LIVMARLI® (maralixibat) oral solution for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS) and Progressive Familial Intrahepatic Cholestasis (PFIC) in Japan.

“We are thrilled to see LIVMARLI approved as the first and only medication available in Japan for patients living with pruritus related to ALGS and PFIC,” said Chris Peetz, chief executive officer at Mirum. “Takeda is a leading global pharmaceutical company with demonstrated success in the development and commercialization of medicines for rare diseases. Under Takeda’s leadership, we are confident that LIVMARLI could have a meaningful impact on the lives of patients with ALGS and PFIC in Japan.”

Mirum and Takeda entered into an exclusive license agreement in September 2021 for the development and commercialization of LIVMARLI for rare cholestatic pediatric liver diseases in Japan. Under the terms of the agreement, Mirum is eligible to receive a percentage of Takeda’s annual net sales.

LIVMARLI is currently approved for the treatment of pruritus related to ALGS in more than 40 countries and for PFIC in more than 30 countries worldwide.

About LIVMARLI® (maralixibat) oral solution

LIVMARLI® (maralixibat) oral solution is an orally administered, ileal bile acid transporter (IBAT) inhibitor approved by the U.S. Food and Drug Administration and European Medicines Agency for two pediatric cholestatic liver diseases. It is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS) in the U.S. three months of age and older and in Europe for patients two months of age and older. It is also approved in the U.S. for the treatment of cholestatic pruritus in patients with progressive familial intrahepatic cholestasis (PFIC) 12 months of age and older and in Europe for the treatment of PFIC in patients three months of age and older. For more information for U.S. residents, please visit LIVMARLI.com.

LIVMARLI is currently being evaluated in the Phase 3 EXPAND study in additional settings of cholestatic pruritus. To learn more about ongoing clinical trials with LIVMARLI, please visit Mirum’s clinical trials section on the company’s website.

U.S. IMPORTANT SAFETY INFORMATION

Limitation of Use: LIVMARLI is not for use in PFIC type 2 patients who have a severe defect in the bile salt export pump (BSEP) protein.

LIVMARLI can cause side effects, including:

Liver injury. Changes in certain liver tests are common in patients with Alagille syndrome and PFIC but can worsen during treatment. These changes may be a sign of liver injury. In PFIC, this can be serious or may lead to liver transplant or death. Your healthcare provider should do blood tests and physical exams before starting and during treatment to check your liver function. Tell your healthcare provider right away if you get any signs or symptoms of liver problems, including nausea or vomiting, skin or the white part of the eye turns yellow, dark or brown urine, pain on the right side of the stomach (abdomen), bloating in your stomach area, loss of appetite or bleeding or bruising more easily than normal.

Stomach and intestinal (gastrointestinal) problems. LIVMARLI can cause stomach and intestinal problems, including diarrhea and stomach pain. Your healthcare provider may advise you to monitor for new or worsening stomach problems including stomach pain, diarrhea, blood in your stool or vomiting. Tell your healthcare provider right away if you have any of these symptoms more often or more severely than normal for you.

A condition called Fat Soluble Vitamin (FSV) Deficiency caused by low levels of certain vitamins (vitamin A, D, E, and K) stored in body fat is common in patients with Alagille syndrome and PFIC but may worsen during treatment. Your healthcare provider should do blood tests before starting and during treatment and may monitor for bone fractures and bleeding which have been reported as common side effects.

US Prescribing Information
EU SmPC
Canadian Product Monograph

About Mirum Pharmaceuticals, Inc.

Mirum Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to transforming the treatment of rare diseases affecting children and adults. Mirum has three approved medications: LIVMARLI® (maralixibat) oral solution, CHOLBAM® (cholic acid) capsules, and CTEXLI™ (chenodiol) tablets.

LIVMARLI, an IBAT inhibitor, is approved for the treatment of two rare liver diseases affecting children and adults. It is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the U.S. (three months and older), in Europe (two months and older), and in other regions globally. It is also approved in the U.S. in cholestatic pruritus in PFIC patients 12 months of age and older; in Europe, it is approved for patients with PFIC three months of age and older. Mirum is also initiating the Phase 3 EXPAND study, a label expansion opportunity for LIVMARLI in additional settings of cholestatic pruritus. CHOLBAM is FDA-approved for the treatment of bile acid synthesis disorders due to single enzyme deficiencies and adjunctive treatment of peroxisomal disorders in patients who show signs or symptoms of liver disease. CTEXLI is FDA-approved for the treatment of cerebrotendinous xanthomatosis (CTX) in adults.

Mirum's late-stage pipeline includes two investigational treatments for several rare diseases. Volixibat, an IBAT inhibitor, is being evaluated in two potentially registrational studies including the Phase 2 VISTAS study for primary sclerosing cholangitis (PSC) and Phase 2b VANTAGE study for primary biliary cholangitis. Volixibat has been granted Breakthrough Therapy Designation for the treatment of cholestatic pruritus in patients with PBC. Mirum is also planning for a Phase 2 study evaluating MRM-3379, a PDE4D inhibitor for the treatment of Fragile X syndrome, a rare genetic neurocognitive disorder.

To learn more about Mirum, visit mirumpharma.com and follow Mirum on Facebook, LinkedIn, Instagram and Twitter (X).

Forward-Looking Statements

Statements contained in this press release regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include statements regarding, among other things, the impact of LIVMARLI on patients in Japan, the ability of Takeda to successfully commercialize in the territory and the size of the Japanese market for LIVMARLI. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Words such as “will,” “could,” “can,” “would,” “potential,” “hope,” “opportunity,” and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon Mirum’s current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, which include, without limitation, risks and uncertainties associated with Mirum’s business in general, the impact of macroeconomic and geopolitical developments, and the other risks described in Mirum’s filings with the Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made and are based on management’s assumptions and estimates as of such date. Mirum undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as required by law. A further description of risks and uncertainties can be found in Mirum’s Quarterly Report on Form 10-K for the quarter ended December 31, 2024 and subsequent filings with the U.S. Securities and Exchange Commission and available at www.sec.gov.

Media Contact:

Erin Murphy

media@mirumpharma.com

Investor Contact:

Andrew McKibben

ir@mirumpharma.com

Source: Mirum Pharmaceuticals, Inc.

FAQ

What is the significance of LIVMARLI's approval in Japan for MIRM stock?

LIVMARLI's approval marks MIRM's entry into the Japanese market as the first and only treatment for ALGS and PFIC, generating revenue through a percentage of Takeda's annual sales.

How many countries has MIRM's LIVMARLI been approved in for ALGS and PFIC?

LIVMARLI is approved in over 40 countries for ALGS-related pruritus and more than 30 countries for PFIC treatment.

When did MIRM partner with Takeda for LIVMARLI's Japanese distribution?

Mirum and Takeda entered into an exclusive license agreement in September 2021 for LIVMARLI's development and commercialization in Japan.

What conditions does LIVMARLI treat in the Japanese market?

LIVMARLI treats cholestatic pruritus in patients with Alagille syndrome (ALGS) and Progressive Familial Intrahepatic Cholestasis (PFIC).
Mirum Pharmaceuticals

NASDAQ:MIRM

MIRM Rankings

MIRM Latest News

MIRM Stock Data

2.29B
41.17M
2.16%
113.24%
13.52%
Biotechnology
Pharmaceutical Preparations
Link
United States
FOSTER CITY